When the ACC and AHA collaborated on new valvular heart disease guidelines in 2020, the two groups highlighted the importance of interventional treatment options such as TAVR. However, an estimated one-third of patients with severe aortic stenosis in the U.S. still lack a guideline-recommended treatment plan.
When the ACC and AHA collaborated on new valvular heart disease guidelines in 2020, the two groups highlighted the importance of interventional treatment options such as TAVR. However, an estimated one-third of patients with severe aortic stenosis in the U.S. still lack a guideline-recommended treatment plan.